175 related articles for article (PubMed ID: 23275306)
1. Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8.
Dian D; Lenhard M; Mayr D; Heublein S; Karsten U; Goletz S; Kuhn C; Wiest I; Friese K; Weissenbacher T; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):239-44. PubMed ID: 23275306
[TBL] [Abstract][Full Text] [Related]
2. Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck.
Wiest I; Alexiou C; Friese K; Betz P; Tübel J; Goletz S; Dian D; Jeschke U
Anticancer Res; 2016 Jun; 36(6):3179-84. PubMed ID: 27272845
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
5. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.
Dian D; Janni W; Kuhn C; Mayr D; Karsten U; Mylonas I; Friese K; Jeschke U
Onkologie; 2009 May; 32(5):238-44. PubMed ID: 19420969
[TBL] [Abstract][Full Text] [Related]
7. TA-MUC1 epitope in non-small cell lung cancer.
Kuemmel A; Single K; Bittinger F; Faldum A; Schmidt LH; Sebastian M; Micke P; Taube C; Buhl R; Wiewrodt R
Lung Cancer; 2009 Jan; 63(1):98-105. PubMed ID: 18539357
[TBL] [Abstract][Full Text] [Related]
8. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas.
Fan XN; Karsten U; Goletz S; Cao Y
Pathol Res Pract; 2010 Aug; 206(8):585-9. PubMed ID: 20400237
[TBL] [Abstract][Full Text] [Related]
9. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
[TBL] [Abstract][Full Text] [Related]
11. PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk A; Stahn R; Faulstich D; Löffler A; Märten A; Karsten U; Goletz S
Cancer Immunol Immunother; 2006 Nov; 55(11):1337-47. PubMed ID: 16485130
[TBL] [Abstract][Full Text] [Related]
12. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
14. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
16. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
17. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
18. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
[TBL] [Abstract][Full Text] [Related]
19. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.
Ahmed N; Riley C; Rice GE; Quinn MA; Baker MS
J Histochem Cytochem; 2002 Oct; 50(10):1371-80. PubMed ID: 12364570
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate epitopes and mucins expressed by 17 human ovarian carcinoma cell lines.
Tamada Y; Iida S; Aoki D; Nozawa S; Irimura T
Oncol Res; 1999; 11(5):233-41. PubMed ID: 10608618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]